➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Moodys
Colorcon
Medtronic
Johnson and Johnson

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210875

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 210875 describes KYNMOBI, which is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from one supplier. There are seventeen patents protecting this drug. Additional details are available on the KYNMOBI profile page.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
Summary for 210875
Tradename:KYNMOBI
Applicant:Sunovion Pharms Inc
Ingredient:apomorphine hydrochloride
Patents:17
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 210875
Generic Entry Date for 210875*:
Constraining patent/regulatory exclusivity:
Dosage:
FILM;SUBLINGUAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 210875
Mechanism of ActionDopamine Agonists
Medical Subject Heading (MeSH) Categories for 210875
Suppliers and Packaging for NDA: 210875
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875 NDA Sunovion Pharmaceuticals Inc. 63402-010 63402-010-30 30 POUCH in 1 CARTON (63402-010-30) > 1 FILM, SOLUBLE in 1 POUCH (63402-010-01)
KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875 NDA Sunovion Pharmaceuticals Inc. 63402-015 63402-015-30 30 POUCH in 1 CARTON (63402-015-30) > 1 FILM, SOLUBLE in 1 POUCH (63402-015-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM;SUBLINGUALStrength10MG
Approval Date:May 21, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:May 21, 2023
Regulatory Exclusivity Use:
Patent:  Get Started for $10Patent Expiration:Jun 11, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:  Get Started for $10Patent Expiration:Apr 19, 2036Product Flag?Substance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
Medtronic
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.